What are the side effects of CJC-1295 & Ipamorelin Blend?

Side effects documented in research include: Mild injection site reactions; Flushing at peak concentrations; Water retention at higher doses. For educational reference only.

Peptide Blends

CJC-1295 & Ipamorelin Blend

A research blend combining CJC-1295 (no DAC / Mod GRF 1-29) with ipamorelin — the most commonly cited GHRH + GHS combination in GH secretagogue research.

C152H252N44O42S / C38H49N9O5Half-life: CJC-1295: ~30-60 min; Ipamorelin: ~2 hours

Community Rating

No ratings yet

Compound Profile

CJC-1295 & Ipamorelin Blend

Key Data

FormulaC152H252N44O42S / C38H49N9O5

Half-lifeCJC-1295: ~30-60 min; Ipamorelin: ~2 hours

CategoryPeptide Blends

Research reference only

Research Focus

Synergistic GH release via GHRHR + GHS-R1a

Selective GH-axis action with minimal off-target effects

Most studied GHRH + GHRP combination in research literature

Preclinical data

⚠ Research & Educational Use Only. CJC-1295 & Ipamorelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.

Chemistry review: Ashish KumarWritten by the KnowYourPeptide Research TeamLast updated October 2026

Our editorial standards →

Key Takeaways

Synergistic GH release via GHRHR + GHS-R1a
Selective GH-axis action with minimal off-target effects
Most studied GHRH + GHRP combination in research literature
CJC-1295 & Ipamorelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.

Research At a Glance

Synergistic GH release via GHRHR + GHS-R1a
Selective GH-axis action with minimal off-target effects
Most studied GHRH + GHRP combination in research literature
Appropriate for long-term body composition research protocols

Calculate CJC-1295 & Ipamorelin Blend dose

Who researches this:Researchers studying combined GHRH + GHRP protocols and synergistic GH releaseThose comparing different GHRP partners for CJC-1295 (ipamorelin vs GHRP-2 vs GHRP-6)People investigating the somatotropic axis and how two mechanistically distinct GH secretagogues combineAdults researching the most common GH-stimulating research peptide combination protocol

💡

In Plain English

Simple summary

The CJC-1295 + Ipamorelin blend is the most popular combination protocol in the research peptide community -- pairing a GHRH analogue (CJC-1295, which tells the pituitary to produce GH) with a ghrelin receptor agonist/GHRP (Ipamorelin, which independently stimulates GH release through the ghrelin pathway). The rationale for combining them is that each works through a different receptor and mechanism, and their effects on GH release are synergistic rather than additive -- the combination produces a GH pulse roughly 4-10 times the magnitude of either compound alone. Ipamorelin's selectivity (minimal cortisol or prolactin elevation compared to other GHRPs) makes it the most frequently chosen GHRP partner for CJC-1295.

Synergistic GH release via GHRHR + GHS-R1a
Selective GH-axis action with minimal off-target effects
Most studied GHRH + GHRP combination in research literature

The full scientific detail, mechanisms, citations, and dosing data, follows below.

What is CJC-1295 & Ipamorelin Blend?

Tap any underlined term for an instant definition.

CJC-1295 & Ipamorelin Blend refers to the combination of CJC-1295 without DAC (identical to Mod GRF 1-29) with ipamorelin. This is the same combination discussed as "Mod GRF 1-29 + Ipamorelin" in the research literature, formulated under the more commercially recognizable CJC-1295 naming convention.

What It Is

CJC-1295 (no DAC) = Mod GRF 1-29: the 4-substitution GHRH analogue without Drug Affinity Complex modification
Ipamorelin: highly selective GHS-R1a agonist
Identical mechanism and expected outcomes to Mod GRF 1-29 + Ipamorelin blend
Note: distinct from CJC-1295 with DAC, which has 6-8 day half-life and produces sustained rather than pulsatile GH elevation

How It Works

CJC-1295 (no DAC) provides GHRHR stimulation with ~30-60 minute half-life
Ipamorelin provides complementary GHS-R1a stimulation and somatostatin suppression
Synergistic GH pulses of 3-4x either peptide alone
Physiological pulsatile GH pattern preserved

Key Research Findings

Same evidence base as Mod GRF 1-29 + Ipamorelin
Most widely used GH-stimulating peptide combination in the research community
Strong safety profile from multiple long-term monitoring studies

Dosing From the Literature

CJC-1295 (no DAC) 100-200 mcg + Ipamorelin 200-300 mcg per injection
Twice daily on empty stomach

Storage and Handling

Lyophilised: 2-8 degrees C; 24 months
Reconstituted: 2-8 degrees C; use within 30 days

By the Numbers

4–10x GH amplification

GHRH + GHRP together produce synergistic GH pulses -- the combination is substantially more potent than either peptide alone

Dual receptor mechanism

CJC-1295 acts on GHRH receptors; Ipamorelin acts on ghrelin receptors (GHS-R1a) -- different receptor systems that amplify each other

Ipamorelin selectivity

Ipamorelin chosen for its minimal cortisol and prolactin elevation vs GHRP-2 and GHRP-6 -- the 'cleanest' GHRP for combination protocols

Key Research Benefits

Documented effects observed in preclinical and clinical studies on CJC-1295 & Ipamorelin Blend. See all Peptide Blends peptides for comparison.

Synergistic GH release via GHRHR + GHS-R1a

Selective GH-axis action with minimal off-target effects

Most studied GHRH + GHRP combination in research literature

Appropriate for long-term body composition research protocols

Side Effects & Risks

Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →

Dosing Data from the Literature

Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.

Research Dosing Protocol

CJC-1295 (no DAC) 100-200 mcg + Ipamorelin 200-300 mcg per injection. Twice daily.

Enter your vial size and target dose to get the exact injection volume.

Administration in Research Settings

Standard reconstitution and administration methodology for laboratory research use.

Subcutaneous injection on empty stomach. Twice daily: morning + bedtime.

What the research doesn't show

Like all GH secretagogue protocols, the combination raises GH and downstream IGF-1 -- which is the goal. Human clinical data for the combination specifically is limited; most clinical research examines the individual components. The synergistic GH amplification is well-supported by physiology, but the specific benefits and risks of long-term combination use in healthy adults are not established by clinical trials.

Medical Expert Videos

Physicians, researchers, and pharmacologists explain CJC-1295 & Ipamorelin Blend, covering mechanisms of action, clinical context, and study findings.

YouTube, CJC-1295 & Ipamorelin Blend · doctors & researchersOpen in YouTube

Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.

📋

The Bottom Line

CJC-1295 & Ipamorelin Blend has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: synergistic gh release via ghrhr + ghs-r1a.

The most commonly reported side effect in research subjects is mild injection site reactions. It is a research chemical, not approved for human use.

Research chemicalNot for human useEducational purposes only

Frequently Asked Questions

Explore Further

All Peptide Blends research peptides Full research peptide directory CJC-1295 & Ipamorelin Blend dose calculator Compare CJC-1295 & Ipamorelin Blend with other peptides Browse all research categories Full site index

Quick Reference

More in Peptide Blends

View all in category

How It Compares

CJC-1295 + GHRP-2 is a more potent (and more cortisol-elevating) alternative. CJC-1295 + GHRP-6 tends to increase appetite more significantly due to GHRP-6's stronger ghrelin activity. Tesamorelin + Ipamorelin is used specifically for visceral fat reduction. Among the GH secretagogue blends, CJC-1295/Ipamorelin has the most widespread community use and is the standard reference combination for most research protocols.

Compare CJC-1295 & Ipamorelin Blend side-by-side

Research Use Only

This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.